Article By:
Fredrik Arnold
Sunday, April 4, 2021 7:55 PM EDT
Should Sanofi's stock trade in the range of $40 to $65 this year, its recent $49.67 price might rise by $10.64 to reach $60.00 by April 5, 2022.
In this article: SNY
There Is Beta In Protalix Stock Due To PRX-102
Isn't that made by Sanofi $SNY?
Protalix BioTherapeutics Pipeline Progress
#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY
Protalix BioTherapeutics Pipeline Progress
My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.